Skip to main content

Table 2 Univariate analysis of PFS and OS

From: Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

  mPFS (95% CI) P mOS (95% CI) P
Age     
  < 56 4.07 (3.27-4.87) 0.937 12.73 (9.46-15.99) 0.453
  ≥ 56 4.70 (3.35-6.04) 13.10 (10.10-16.09)
Sex     
  Male 4.27 (3.49-5.04) 0.915 12.10 (10.43-13.76) 0.072
  Female 4.43 (2.02-6.83) 15.37 (11.48-19.25)
Location     
  GEJ-cardia 3.83 (1.16-6.49) 0.926 14.03 (4.50-23.55) 0.903
  Body 4.7 (3.95-5.44) 12.37 (9.17-15.56)
  Antrum 3.93 (0.47-4.38) 14.17 (11.14-17.19)  
Differentiation     
  Well, moderately differentiated 3.83 (3.49-4.16) 0.530 12.10 (7.79-16.40) 0.200
  Poorly, signet ring cell type 4.67 (3.77-5.56) 13.13 (10.19-16.06)
Lauren classification     
  Intestinal 4.20 (3.29-5.10) 0.479 13.10 (9.95-16.24) 0.626
  Diffuse 4.27 (2.85-5.68) 13.13 (9.62-16.63)
  Mixed 4.93 (2.20-7.65) 11.70 (2.55-20.84)
Disease status     
  Recurrence after curative resection 4.20 (3.13-5.26) 0.714 12.10 (9.69-14.50) 0.962
  Initial metastasis 4.43 (3.36-5.49) 14.17 (11.10-17.23)
Liver metastasis     
  Yes 4.70 (2.89-6.50) 0.537 14.03 (9.13-18.9) 0.586
  No 4.27 (3.49-5.04) 13.10 (10.06-16.14)
Bone metastasis     
  Yes 4.70 (0.82-8.57) 0.368 9.77 (4.92-14.62) 0.685
  No 4.27 (3.53-5.00) 13.13 (10.76-15.49)
Peritoneal metastasis     
  Yes 4.57 (2.97-6.16) 0.249 12.73 (9.04-16.41) 0.887
  No 3.97 (3.15-4.78) 13.10 (9.81-16.38)
Chemotherapy response     
  CR, PR 4.73 (3.12-6.33) 0.341 11.43 (8.06-14.80) 0.192
  SD, PD 3.97 (3.16-4.77) 15.03 (12.33-17.72)
Chemotherapeutic regimen     
  Paclitaxel/cisplatin 4.07 (3.52-4.61) 0.224 12.37 (10.23-14.50) 0.221
  Docetaxel/cisplatin 6.50 (5.71-7.28) 17.87 (14.42-21.31)
No. of involved organs     
  1 3.97 (3.17-4.76) 0.220 12.10 (9.15-15.04) 0.570
  2 4.73 (2.76-6.70) 15.13 (10.11-20.14)
  ≥ 3 7.07 (0.00-16.05) 12.40 (9.91-14.88)
TUBB3     
  High-level expression 3.63 (3.37-3.88) 0.001 13.13 (9.88-16.37) 0.769
  Low-level expression 6.67 (5.65-7.68) 13.10 (8.83-17.36)
ERCC1     
  High-level expression 3.77 (3.54-3.99) 0.280 12.70 (9.45-15.94) 0.916
  Low-level expression 5.23 (3.74-6.71) 13.53 (10.10-16.95)
  1. mPFS, median progression-free survival; mOS, median overall survival; GEJ, gastrointestinal junction; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TUBB3, class III β-tubulin; ERCC1, excision repair cross-complementation group 1.